Polycystic Kidney Disease – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Polycystic Kidney Disease – Pipeline Review, H2 2019’, provides an overview of the Polycystic Kidney Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease

– The report reviews pipeline therapeutics for Polycystic Kidney Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Polycystic Kidney Disease therapeutics and enlists all their major and minor projects

– The report assesses Polycystic Kidney Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Angion Biomedica Corp

Bristol-Myers Squibb Co

DiscoveryBiomed Inc

Eloxx Pharmaceuticals Inc

Genzyme Corp

GLG Pharma SA

Goldfinch Biopharma Inc

IC-MedTech Inc

Ipsen SA

Kadmon Corp LLC

ManRos Therapeutics

Mironid Ltd

NovaTarg Therapeutics Inc

Palladio Biosciences Inc

Reata Pharmaceuticals Inc

Regulus Therapeutics Inc

XORTX Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Kidney Disease - Overview

Polycystic Kidney Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Kidney Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Kidney Disease - Companies Involved in Therapeutics Development

Angion Biomedica Corp

Celgene Corp

Conatus Pharmaceuticals Inc

DiscoveryBiomed Inc

Genzyme Corp

IC-MedTech Inc

Ipsen SA

Kadmon Corp LLC

ManRos Therapeutics

Mironid Ltd

NovaTarg Therapeutics Inc

Q BioMed Inc

Reata Pharmaceuticals Inc

Polycystic Kidney Disease - Drug Profiles

(sodium ascorbate + menadione sodium bisulfite) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3586 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bardoxolone methyl - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBM-43H11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Cystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibiglustat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-8050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lixivaptan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

menadione sodium bisulfite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxypurinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PKD-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PKD-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PKD-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrimethamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ricolinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PDE4 for Polycystic Kidney Disease and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit STAT3 for Oncology and Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesevatinib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycystic Kidney Disease - Dormant Projects

Polycystic Kidney Disease - Discontinued Products

Polycystic Kidney Disease - Product Development Milestones

Featured News & Press Releases

Sep 10, 2018: XORTX announces submission of Orphan Drug Designation Application

Aug 13, 2018: XORTX submits FDA pre-IND meeting documents

Jul 23, 2018: Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease

Jun 08, 2018: XORTX Announces Filing of FDA pre-IND Meeting Request Letter

May 25, 2018: Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study

Feb 27, 2018: Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials

Nov 13, 2017: Kadmon Initiates Phase 2 Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease

Nov 01, 2017: Palladio Biosciences Announces Presentations of New Data for Lixivaptan and Polycystic Kidney Disease during the American Society of Nephrology 2017 Annual Meeting

Oct 04, 2017: Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Jun 12, 2017: Palladio Biosciences Announces Appointment of Frank C. Condella, Jr. to Board of Directors

Jan 30, 2017: Mironid announces additional non-dilutive funding through an Early Stage Award from Innovate UK’s Biomedical Catalyst 2016

Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016

Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015

Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases

Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Polycystic Kidney Disease, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Polycystic Kidney Disease – Pipeline by Angion Biomedica Corp, H2 2019

Polycystic Kidney Disease – Pipeline by Bristol-Myers Squibb Co, H2 2019

Polycystic Kidney Disease – Pipeline by DiscoveryBiomed Inc, H2 2019

Polycystic Kidney Disease – Pipeline by Eloxx Pharmaceuticals Inc, H2 2019

Polycystic Kidney Disease – Pipeline by Genzyme Corp, H2 2019

Polycystic Kidney Disease – Pipeline by GLG Pharma SA, H2 2019

Polycystic Kidney Disease – Pipeline by Goldfinch Biopharma Inc, H2 2019

Polycystic Kidney Disease – Pipeline by IC-MedTech Inc, H2 2019

Polycystic Kidney Disease – Pipeline by Ipsen SA, H2 2019

Polycystic Kidney Disease – Pipeline by Kadmon Corp LLC, H2 2019

Polycystic Kidney Disease – Pipeline by ManRos Therapeutics, H2 2019

Polycystic Kidney Disease – Pipeline by Mironid Ltd, H2 2019

Polycystic Kidney Disease – Pipeline by NovaTarg Therapeutics Inc, H2 2019

Polycystic Kidney Disease – Pipeline by Palladio Biosciences Inc, H2 2019

Polycystic Kidney Disease – Pipeline by Reata Pharmaceuticals Inc, H2 2019

Polycystic Kidney Disease – Pipeline by Regulus Therapeutics Inc, H2 2019

Polycystic Kidney Disease – Pipeline by XORTX Therapeutics Inc, H2 2019

Polycystic Kidney Disease – Dormant Projects, H2 2019

Polycystic Kidney Disease – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Polycystic Kidney Disease, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports